IRB #

IRB00008932

Title

SARC022: A Phase 2 Study of OSI-906 in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors

Principal Investigator

Michael Heinrich

Study Purpose

The purpose of this study is to determine the effects (good and/or bad) of OSI-906 on patients diagnosed with wild-type Gastrointestinal Stromal tumors (GIST) cancer.

Medical Condition(s)

Wild-type GIST

Eligibility Criteria

1. Male or female age 18 or older
2. Confirmed diagnosis of GIST with wild-type genotype
3. For patients diagnosed with GIST at age 18 or younger, must have received Sutent (Sunitinib) as a prior treatment regimen
4. For patients diagnosed with GIST at age 19 or older, must have received Gleevec (Imatinib) as a prior treatment regimen

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Until disease progression or unacceptable side effect

Minors Included

No

Contact

Tracy Walker, RN
(503) 346-1183

Sponsor

Cancer Therapy Evaluation Program (CTEP) and the National Cancer Institute (NCI) and SARC (Sarcoma Alliance for Research through Collaboration) is the Coordinating Center.

Recruitment End

04/01/2014

Compensation Provided

No